Nicola R Harker
Overview
Explore the profile of Nicola R Harker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghiboub M, Bell M, Sinkeviciute D, Prinjha R, de Winther M, Harker N, et al.
Curr Issues Mol Biol
. 2023 May;
45(5):4228-4245.
PMID: 37232738
SP140 is an epigenetic reader protein expressed predominantly in immune cells. GWAS studies have shown an association between single nucleotide polymorphisms (SNPs) and diverse autoimmune and inflammatory diseases, suggesting a...
2.
Quintela M, James D, Garcia J, Edwards K, Margarit L, Das N, et al.
Br J Cancer
. 2023 Apr;
129(1):163-174.
PMID: 37120667
Background: Epigenomic dysregulation has been linked to solid tumour malignancies, including ovarian cancers. Profiling of re-programmed enhancer locations associated with disease has the potential to improve stratification and thus therapeutic...
3.
Quintela M, James D, Pociute A, Powell L, Edwards K, Coombes Z, et al.
Clin Epigenetics
. 2023 Apr;
15(1):63.
PMID: 37060086
Background: Ovarian cancer has a specific unmet clinical need, with a persistently poor 5-year survival rate observed in women with advanced stage disease warranting continued efforts to develop new treatment...
4.
Ghiboub M, Koster J, Craggs P, Li Yim A, Shillings A, Hutchinson S, et al.
BMC Biol
. 2022 Aug;
20(1):182.
PMID: 35986286
Background: SP140 is a bromodomain-containing protein expressed predominantly in immune cells. Genetic polymorphisms and epigenetic modifications in the SP140 locus have been linked to Crohn's disease (CD), suggesting a role...
5.
Ghiboub M, Elfiky A, de Winther M, Harker N, Tough D, de Jonge W
J Pers Med
. 2021 Apr;
11(5).
PMID: 33922725
Histone deacetylases (HDACs) and bromodomain-containing proteins (BCPs) play a key role in chromatin remodeling. Based on their ability to regulate inducible gene expression in the context of inflammation and cancer,...
6.
Ghiboub M, Zhao J, Li Yim A, Schilderink R, Verseijden C, van Hamersveld P, et al.
Front Immunol
. 2020 Oct;
11:550769.
PMID: 33123128
Histone deacetylases (HDACs) are a group of enzymes that control histone deacetylation and bear potential to direct expression of large gene sets. We determined the effect of HDAC inhibitors (HDACi)...
7.
Gilan O, Rioja I, Knezevic K, Bell M, Yeung M, Harker N, et al.
Science
. 2020 Mar;
368(6489):387-394.
PMID: 32193360
The two tandem bromodomains of the BET (bromodomain and extraterminal domain) proteins enable chromatin binding to facilitate transcription. Drugs that inhibit both bromodomains equally have shown efficacy in certain malignant...
8.
Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry M, et al.
Blood
. 2013 Dec;
123(5):697-705.
PMID: 24335499
The bromodomain and extraterminal (BET) protein BRD2-4 inhibitors hold therapeutic promise in preclinical models of hematologic malignancies. However, translation of these data to molecules suitable for clinical development has yet...